Epithalon vs Vesugen
Side-by-side comparison of key properties, dosing, and research.
- Summary
- Epithalon is a synthetic tetrapeptide developed from the pineal gland extract Epithalamin by Russian scientist Dr. Vladimir Khavinson. It is one of the most researched longevity peptides, known for activating telomerase and extending telomere length — the molecular hallmarks of cellular aging.
- Vesugen is a tripeptide bioregulator (Lys-Glu-Asp) developed by Professor Vladimir Khavinson, tissue-specific for blood vessels and the vascular endothelium. It supports endothelial cell function, promotes vascular wall integrity, and is studied for atherosclerosis prevention, vascular aging, and cardiovascular health maintenance. It is one of the more broadly applicable Khavinson bioregulators given the ubiquity of vascular tissue.
- Half-Life
- 2–4 hours
- Short (minutes); sustained gene-regulatory effects
- Admin Route
- SubQ, Sublingual
- SubQ, Oral
- Research
- —
- —
- Typical Dose
- 5–10 mg total per cycle
- 10 mg per day
- Frequency
- 0.5–1 mg daily
- Daily for 10–30 days
- Key Benefits
- Activates telomerase enzyme, extending telomere length
- May slow cellular and biological aging
- Regulates melatonin production and circadian rhythms
- Improves sleep quality
- Powerful antioxidant properties
- May reduce incidence of age-related diseases
- Supports immune system function
- Studied for cancer prevention properties in animal models
- Supports vascular endothelial cell function and integrity
- May reduce endothelial inflammation and dysfunction
- Anti-aging effects on blood vessel walls
- Potential benefits in early atherosclerosis and vascular aging
- Supports nitric oxide-mediated vascular tone
- Reduces endothelial apoptosis from oxidative stress
- Complementary to Cardiogen and Epithalon in cardiovascular longevity protocols
- Side Effects
- Injection site irritation (mild)
- Temporary sleep changes during cycle (usually improves)
- Rare: fatigue
- Generally well tolerated
- Mild injection site reactions
- No significant vascular adverse events reported at standard doses
- Stacks With
- —
- —